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A wonder drug 
against cancer, 
HIV and other 
diseases?
Researchers at the Massey Cancer Center have 
found that AR-12 can neutralize the proteins 
that protect cancer cells. The drug also may 
be effective against Ebola, Zika and bacterial 
infections.
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Chaperones make sure students stick together during class field trips. The cells in your body 
have chaperones, too: “chaperone” proteins that 
keep a cell’s shape intact. Usually, that’s good. 
But when someone has cancer, these proteins 
allow cancer cells to reproduce and spread 
throughout the body.
So a VCU researcher has found a way to ditch 
those annoying chaperone proteins – and stop 
the spread of cancer – just like students might 
ditch their chaperones on a field trip.
Dr. Paul Dent, a researcher at VCU’s Massey 
Cancer Center, is experimenting with a new drug 
that targets the chaperone proteins that protect 
cancer cells.
The drug, called AR-12, overrides the 
chaperones from holding a cell’s shape. AR-12 
does its damage by breaking apart the host cell, 
which is needed for cancer cells to reproduce 
(otherwise they’ll die). This secret weapon has 
the potential to fight off not only cancer but also 
Ebola, Zika and the human immunodeficiency 
virus, as well as bacterial infections.
“We saw interesting effects with the AR-12 drug 
against those viruses and against bacteria,” Dent 
said.
He said cancer cells are very active, thus 
creating more enzymes. Once the cancer 
attaches to a cell, chaperone proteins stick with 
the enzyme and keep it together. But AR-12 can 
render the chaperones useless.
“These proteins are flopping around like a 
jellyfish out of water when they’re catalyzing, 
which means they can fall out of shape easily,” 
Dent said. “And if they fall out of shape, they’re 
dead.”
The chaperones protect the cancer by giving it 
a safe place to live. “The chaperone is snuggled 
up to the enzyme,” Dent said. “And if the enzyme 
should ever get a bit incorrectly shaped, the 
chaperone spends some ATP (adenosine 
triphosphate) energy and keeps it together.”
You can’t destroy the cancer while the 
chaperones are protecting it. And neutralizing 
the chaperones is tricky because there is more 
than one kind.
One family of chaperone proteins is called 
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Dr. Paul Dent, center, and his team of researchers at the Massey 
Cancer Center. (Photo courtesy of Dr. Dent)
‘We saw interesting 
effects with the AR-
12 drug against those 
viruses and against 
bacteria,’ Dent says.
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You can’t destroy 
the cancer while 
the chaperones are 
protecting it. And 
neutralizing the 
chaperones is tricky 
because there is more 
than one kind.
HSP90; another is HSP70. Dent said that when 
HSP90 is attacked, HSP70 is formed – and vice 
versa. This has posed issues for researchers 
because when they target one chaperone family, 
a different one replaces it and protects the cell.
Previous chaperone inhibitors could target only 
HSP90 or HSP70. This where the drug AR-12 
is useful: It blocks both the HSP90 and HSP70 
families.
“Unlike many drugs that target one specifically, 
this drug targets both, albeit not as potently,” 
Dent said. When AR-12 prevents the chaperones 
from holding a cell together, the cell loses its 
shape and kills the cancer.
But this possible wonder drug is not on the 
market yet. Research has been done on AR-
12 for years now, but the drug’s owner, Arno 
Therapeutics, is still seeking approval from the 
U.S. Food and Drug Administration.
“AR-12 was tested in cancer patients. Although 
it was safe and showed some activity, the drug 
uptake in patients was variable,” Dent said. “So 
the FDA told Arno Therapeutics they needed to 
reformulate AR-12 before doing more clinical 
work.”
Dent said he is disappointed that the company 
hasn’t reformulated the drug so that testing can 
resume.
On its website, Arno Therapeutics describes 
itself as “a biopharmaceutical company that 
focuses on the clinical development of targeted 
cancer therapies and novel drug candidates for 
unmet medical needs.” •
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